Enza Lacivita1, Igor A Schepetkin2, Madia L Stama1, Liliya N Kirpotina2, Nicola A Colabufo1, Roberto Perrone1, Andrei I Khlebnikov3, Mark T Quinn2, Marcello Leopoldo4. 1. Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari 'Aldo Moro', via Orabona, 4, 70125 Bari, Italy. 2. Department of Microbiology and Immunology, Montana State University, Bozeman, MT 59717, USA. 3. Department of Chemistry, Altai State Techical University, Barnaul, Russia; Department of Biotechnology and Organic Chemistry, Tomsk Polytechnic University, Tomsk 634050, Russia. 4. Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari 'Aldo Moro', via Orabona, 4, 70125 Bari, Italy. Electronic address: marcello.leopoldo@uniba.it.
Abstract
N-Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) that play critical roles in inflammatory reactions, and FPR-specific interactions can possibly be used to facilitate the resolution of pathological inflammatory reactions. We here report the synthesis and biological evaluation of six pairs of chiral ureidopropanamido derivatives as potent and selective formyl peptide receptor-2 (FPR2) agonists that were designed starting from our lead agonist (S)-3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]-N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]propanamide ((S)-9a). The new compounds were obtained in overall yields considerably higher than (S)-9a. Several of the new compounds showed agonist properties comparable to that of (S)-9a along with higher selectivity over FPR1. Molecular modeling was used to define chiral recognition by FPR2. In vitro metabolic stability of selected compounds was also assessed to obtain preliminary insight on drug-like properties of this class of compounds.
Nn class="Chemical">-Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) that play critical roles in inflammatory reactions, andFPR-specific interactions can possibly be used to facilitate the resolution of pathological inflammatory reactions. We here report the synthesis and biological evaluation of six pairs of chiral ureidopropanamido derivatives as potent and selective formyl peptide receptor-2 (FPR2) agonists that were designed starting from our lead agonist (S)-3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]-N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]propanamide ((S)-9a). The new compounds were obtained in overall yields considerably higher than (S)-9a. Several of the new compounds showed agonist properties comparable to that of (S)-9a along with higher selectivity over FPR1. Molecular modeling was used to define chiral recognition by FPR2. In vitro metabolic stability of selected compounds was also assessed to obtain preliminary insight on drug-like properties of this class of compounds.
Authors: S B Su; W H Gong; J L Gao; W P Shen; M C Grimm; X Deng; P M Murphy; J J Oppenheim; J M Wang Journal: Blood Date: 1999-06-01 Impact factor: 22.113
Authors: Roland W Bürli; Han Xu; Xiaoming Zou; Kristine Muller; Jennifer Golden; Mike Frohn; Matthew Adlam; Matthew H Plant; Min Wong; Michele McElvain; Kelly Regal; Vellarkad N Viswanadhan; Philip Tagari; Randall Hungate Journal: Bioorg Med Chem Lett Date: 2006-05-11 Impact factor: 2.823
Authors: R S Obach; J G Baxter; T E Liston; B M Silber; B C Jones; F MacIntyre; D J Rance; P Wastall Journal: J Pharmacol Exp Ther Date: 1997-10 Impact factor: 4.030
Authors: Madia L Stama; Enza Lacivita; Liliya N Kirpotina; Mauro Niso; Roberto Perrone; Igor A Schepetkin; Mark T Quinn; Marcello Leopoldo Journal: ChemMedChem Date: 2017-11-07 Impact factor: 3.466
Authors: Terry W Moody; Nicole Tashakkori; Samuel A Mantey; Paola Moreno; Irene Ramos-Alvarez; Marcello Leopoldo; Robert T Jensen Journal: Front Endocrinol (Lausanne) Date: 2017-07-21 Impact factor: 5.555